real peptides FAQ

Discard it immediately. Cloudiness or visible particles indicate protein aggregation. A sign the peptide has denatured due to temperature excursion, contamination, or improper mixing. Denatured peptides are biologically inactive and potentially immunogenic. Proper reconstitution produces a clear, colorless solution. If cloudiness appears immediately after mixing, the issue is likely improper storage of the lyophilized powder or using the wrong diluent (use only bacteriostatic water, never saline or sterile water without preservative).

No. Thymalin and immunosuppressants work through opposing mechanisms. Thymalin activates T-cell proliferation; drugs like methotrexate, azathioprine, or corticosteroids suppress it. The interaction isn't just ineffective. It's counterproductive. If you're tapering off immunosuppressants under medical supervision, wait until you've been off the medication for at least 4 weeks (one full T-cell turnover cycle) before starting Thymalin. This washout period ensures the thymus isn't receiving simultaneous activation and suppression signals.

Choose P21 if your goal is improving retention and recall of new information. Its mechanism (CREB pathway activation) directly enhances long-term potentiation, the cellular basis of memory consolidation. Choose dihexa if you're addressing impaired learning capacity or cognitive flexibility. Its synaptogenic effect creates new connections rather than strengthening existing ones. The two compounds operate through non-overlapping pathways, making them theoretically complementary, though no published research has evaluated combined protocols.

Initiate supportive therapy but expect limited motor benefit. The Vienna trial data showed efficacy only in patients within 18 months of diagnosis. Beyond that window, dopaminergic cell loss exceeds 60–70% in the substantia nigra, and neurotrophic peptides can't reverse structural atrophy. Late-stage administration may still provide modest cognitive support through hippocampal BDNF upregulation, but motor symptom reversal is unlikely.

Combination protocols require separate dosing schedules. Cerebrolysin and P21 operate through complementary mechanisms and can theoretically be co-administered, but no published data validates safety or synergistic efficacy in TBI models. If combining, administer via separate injection sites to prevent chemical interaction. Monitor for unexpected mortality or behavioral abnormalities. Sequential administration (Cerebrolysin at injury, P21 at 24 hours) may reduce interaction risk while targeting different phases of secondary injury.

Get baseline imaging (MRI or ultrasound) before starting and schedule follow-up imaging 6–8 weeks post-intervention to objectively measure healing progress. Attia's framework requires measurable endpoints—subjective 'feels better' isn't sufficient. Dosing protocols typically range from 250–500mcg daily via subcutaneous injection near the injury site, but without physician oversight and imaging confirmation, you're guessing whether the peptide is working or if you're experiencing placebo effect compounded by natural healing.

Contact your supplier immediately to verify all documentation was included with the shipment. Customs officers detain peptide imports primarily when documentation is incomplete or contradictory. Missing certificates of analysis, vague product descriptions on invoices, or labelling that suggests human use. Real Peptides includes pre-clearance documentation with every UK-bound order, but if customs requests additional verification, the supplier can provide manufacturing records, GMP certifications, and clarification letters directly to customs officials. Detention typically resolves within 5–7 business days once proper documentation is submitted.

Don't start without baseline bloodwork measuring IGF-1, fasting glucose, HbA1c, and a comprehensive metabolic panel. Elevated IGF-1 accelerates cell proliferation, which is beneficial for muscle growth and tissue repair but dangerous if you have undiagnosed pre-cancerous lesions. Attia has stated explicitly that manipulating the GH/IGF-1 axis without understanding your baseline risk profile is reckless. If your IGF-1 is already in the upper quartile for your age, adding a secretagogue pushes you into supraphysiological territory with unknown long-term consequences.

Administer the missed dose as soon as you remember and resume the regular every-3-day schedule from that point. Missing one injection by 48 hours doesn't reset the protocol. The thymic regulatory cascade from previous doses remains active for 72+ hours, so a brief delay doesn't erase prior immune modulation. If more than 5 days have passed since the last injection, treat it as the next scheduled dose in the series rather than a missed dose. Don't compress two injections into a short window to 'catch up.'

Don't. The temperature control required for P21 stability makes inter-site shipping of reconstituted solutions impractical without pharmaceutical-grade cold chain logistics. Ship lyophilized powder on dry ice with temperature dataloggers, then reconstitute on-site. If reconstituted peptide absolutely must be transported, use an actively cooled medical transport container maintaining 2–8°C throughout transit, limit shipping time to under 24 hours, and include temperature-sensitive indicator strips in the packaging. Upon receipt, inspect for precipitation or color change. Any visible aggregation indicates compromised peptide and the vial should be discarded. For Adamax, the same principles apply though the compound tolerates brief temperature excursions better than P21. Real Peptides supplies both compounds with detailed handling protocols specifically to prevent integrity loss during storage and transport.

It depends on the compound and your institutional setting. Survodutide and mazdutide are available through FDA-registered 503B compounding facilities like Real Peptides, which prepare peptides under USP standards for research use. Retatrutide is investigational-only. Access requires enrollment in a pharmaceutical company's sponsored clinical trial, which limits availability to approved research sites. If your protocol allows compounded peptides, survodutide and mazdutide offer dual-pathway engagement without the access restrictions of investigational-only compounds.

Most peptide side effects are dose-dependent and fully reversible upon discontinuation. MK-677 commonly causes water retention and increased appetite. Reducing dose by 50% typically resolves both. GHSs can cause transient numbness or tingling in the hands (carpal tunnel-like symptoms) due to fluid retention. This resolves within 2–4 weeks as the body adapts. Thymalin rarely causes side effects but may trigger mild immune activation symptoms (fatigue, low-grade fever) during the first 2–3 injections as T-cell production ramps up. If side effects persist beyond dose reduction, discontinue the peptide and consult a qualified healthcare provider.

UK peptide laws don't require institutional affiliation for research peptide imports, but customs officers may request evidence of legitimate research intent if you're importing as an individual. This can include documentation of a registered home laboratory, correspondence with academic collaborators, or records of published research involving peptides. Real Peptides recommends individual researchers maintain a research log or project documentation that can be provided to customs if questioned. The key compliance factor isn't where you work. It's proving the peptides are for non-human research, not personal therapeutic use.

Tesofensine's dopaminergic and serotonergic activity complicates its use in populations with psychiatric histories. The compound was originally developed as an antidepressant, and though it failed that indication, it still modulates CNS reward pathways. Researchers must screen for substance use history and current SSRI/SNRI use to avoid serotonin syndrome. 5-Amino-1MQ has no psychoactive properties and poses no contraindication for mood disorder populations.

Use both compounds in separate experimental arms rather than combining them in a single treatment group. Co-administration introduces confounding variables because AMPK activation (Adamax) and CNTF signaling (P21) can interact at the transcriptional level through overlapping STAT3 and CREB phosphorylation. A cleaner experimental design treats one group with P21 to isolate neuroplasticity effects, another with Adamax to isolate metabolic effects, and compares both to vehicle controls. If the research question genuinely requires simultaneous metabolic and cognitive modulation, stagger dosing by at least 6 hours to minimize acute signaling crosstalk, and include pathway-specific readouts (dendritic spine counts for P21, AMPK phosphorylation for Adamax) to verify independent pathway engagement.

Structural identity to a pharmaceutical compound doesn't automatically prohibit research peptide sourcing. Tirzepatide, semaglutide, and other GLP-1 receptor agonists are legal to import as research-grade peptides when purchased without therapeutic marketing claims. The MHRA focuses on intended use, not molecular structure. Purchase from a supplier that labels the peptide for research only, includes batch documentation, and avoids any language suggesting human therapeutic application. If your research involves compounds on the controlled substances list (very few peptides qualify), verify import requirements with MHRA before ordering.

5-Amino-1MQ is the appropriate choice. Its mechanism. NNMT inhibition leading to increased NAD+ and mitochondrial fat oxidation. Doesn't involve CNS appetite pathways. Preclinical data shows weight reduction occurs even in ad libitum feeding conditions, meaning caloric intake isn't restricted. This makes it suitable for studies exploring metabolic flexibility, substrate utilisation shifts, or interventions where maintaining normal eating behaviour is essential.

Yes. Tirzepatide's dual GLP-1/GIP mechanism produces higher rates of gastrointestinal adverse events during dose escalation than cagrilintide. SURMOUNT-1 reported nausea in 31% of tirzepatide patients versus 18% in the cagrilintide arm of the REWIND trial. The difference is GLP-1 receptor density in the gut. Higher activation slows gastric emptying more aggressively, which amplifies nausea but also produces greater weight loss. Titrating slowly (4-week intervals between dose increases) allows GLP-1 receptor downregulation to catch up with dose, reducing discontinuation rates.

Discard it. An 8-hour ambient temperature exposure (20–25°C) causes 18–28% potency loss depending on the specific peptide sequence and solution pH. You cannot determine the extent of degradation without HPLC analysis, which costs more than replacing the vial. The degradation is cumulative and irreversible. Re-refrigerating does not restore lost potency. For high-value peptides, some researchers run a pilot dose on a single test subject to assess response before committing the full cohort, but this introduces experimental variability that undermines statistical power.

Avoid tesofensine. The Phase 2 trial documented consistent heart rate increases of 7–9 bpm and modest systolic BP elevations across all dose groups. Effects that require regular cardiovascular assessment. 5-Amino-1MQ, by contrast, showed no cardiovascular signals in animal studies and doesn't engage sympathomimetic pathways. For protocols without cardiac monitoring infrastructure, 5-Amino-1MQ is the safer metabolic intervention.